For glioma phenotyping, IDH1/2, 1p/19q, MGMT, hTERT, TP53, PTEN, EGFR, and ATRX mutations are usually regarded as the key factors influencing postoperative therapeutic decisions, such as radiotherapy, chemotherapy, molecular targeted therapy and immune therapy (37). Here, ATRX is linked to glioma.